<DOC>
	<DOCNO>NCT00496301</DOCNO>
	<brief_summary>Main Objective : To evaluate progression-free survival patient unresectable renal cell carcinoma ( RCC ) treat combination gemcitabine , capecitabine , sorafenib .</brief_summary>
	<brief_title>Clinical Trial Mixture G , C S Treatment Patients With RCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must give write informed consent procedure relate study perform ; therefore , must give selection visit . The patient must inform right withdraw study time , without kind prejudice . Patients renal clear cell carcinoma ( RCC ) , unresectable and/or metastatic , histologically cytologically document ( exclude less common subtypes ) . Patients must candidate immunotherapeutic treatment , accord response predictive factor , must intolerant immunotherapeutic treatment . Patients classify median low risk , accord Motzer 's scoring . Patients ( men woman ) age equal superior 18 year old . ECOG ≤ 1 . Assessable measurable disease . Patients adequate haematological function , define : Neutrophils ≥ 1.5 x 10^9/L Blood platelet ≥ 100 x 10^9/L Haemoglobin ≥ 10 g/dl Patients adequate hepatic , renal , medullar coagulation function , accord follow criterion : Total bilirubin &lt; 1.5 time superior limit normality ALT AST &lt; 2.5 time superior limit normality ( &lt; 5 time superior limit normality case liver failure due cancer ) Amylase lipase &lt; 1.5 time superior limit normality Serum creatinine &lt; 2 time superior limit normality TP INR TTP &lt; 1.5 time superior limit normality . If patient receiving anticoagulant , strict monitoring carry , evaluation weekly basis , least , INR stable , refer determination previous dose administration , accord local standard care . Patients life expectancy superior 12 week , least . Patients may receive radiotherapy ; however , must target lesion . Patients sex must use adequate contraceptive method ( oral injectable contraceptive , intrauterine device , condom , sterilization ) whilst participate protocol . After retreat treatment BAY 439006 , contraceptive method must use 4 week woman 3 month men . Patients capable accomplish study 's requirement without impediment follow instruction study Patients give write informed consent participate study . Patients less common RCC subtypes , pure papillary cell tumour , Bellini carcinoma , medullary carcinoma oncocytic chromophobes sarcomatoid variant , exclude study . Patients receive previous treatment chemotherapy tumours evolve immunotherapy treatment . Patients , due characteristic , may obtain potential benefit immunotherapy treatment . Patients receive previous antiangiogenic treatment . Highrisk patient accord Motzer 's classification . Concomitant treatment another chemotherapy immunotherapy . Arterial uncontrolled hypertension , define systolic arterial pressure value &gt; 150 mmHg diastolic arterial pressure value &gt; 90 mmHg , despite adequate medical treatment . Patients primary cancer diagnosis different RCC , except situ cervical carcinoma , baseline cellular carcinoma superficial bladder tumour , prostate cancer pT1 gleason &lt; 6 malign tumour receive curative treatment &gt; 5 year previous inclusion study . Cardiac arrhythmia antecedent , require treatment antiarrhythmic ( except betablockers digoxin ) , symptomatic coronary disease ischemia ( myocardial infarction previous 6 month ) congestive cardiac insufficiency &gt; New York Heart Association ( NYHA ) class II Patients active bacterial fungal infectious process , consider severe clinical point view ( ≥ Common Terminology Criteria National Cancer Institute [ CTC NCI ] grade 2 , version 3 ) Patients present previously know positive serology HIV chronic hepatitis B C. Antecedents organ allograft . Meningeal carcinomatosis symptomatic uncontrolled cerebral disease . Patients epileptic disorder require medication ( antiepileptic ) . All unstable condition could put patient 's security and/or study accomplishment danger . Abuse substance , clinical condition , psychological social , may interfere patient 's participation study evaluation study 's result . Patients present contraindication allergy study 's investigational product . Patients participate participate clinical trial 4 week previous inclusion . Pregnant breastfeed woman . Women fertile age must negative result pregnancy test perform 7 day begin administration study medication . Both men woman include study must use adequate contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>renal</keyword>
	<keyword>sorafenib</keyword>
	<keyword>Unresectable and/or metastatic renal cell cancer</keyword>
</DOC>